Becton, Dickinson and Company (BDX): Price and Financial Metrics


Becton, Dickinson and Company (BDX)

Today's Latest Price: $241.09 USD

4.69 (1.98%)

Updated Oct 22 4:00pm

Add BDX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 142 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

BDX Stock Summary

  • Becton Dickinson & Co's market capitalization of $68,524,925,456 is ahead of 97.2% of US-listed equities.
  • BDX's went public 34.83 years ago, making it older than 92.9% of listed US stocks we're tracking.
  • In terms of volatility of its share price, BDX is more volatile than only 2.31% of stocks we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Becton Dickinson & Co are ZTS, BSX, SYK, MELI, and ABB.
  • BDX's SEC filings can be seen here. And to visit Becton Dickinson & Co's official web site, go to www.bd.com.

BDX Stock Price Chart Interactive Chart >

Price chart for BDX

BDX Price/Volume Stats

Current price $241.09 52-week high $286.72
Prev. close $236.40 52-week low $197.75
Day low $235.48 Volume 1,096,090
Day high $241.42 Avg. volume 1,914,712
50-day MA $238.98 Dividend yield 1.34%
200-day MA $248.96 Market Cap 69.88B

Becton, Dickinson and Company (BDX) Company Bio


Becton, Dickinson and Company provides solutions which are focused on improving medication management and patient safety, supporting infection prevention practices, equipping surgical and interventional procedures, improving drug delivery, aiding anesthesiology and respiratory care, advancing cellular research and applications, enhancing the diagnosis of infectious diseases and cancers, and supporting the management of diabetes. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.

BDX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$241.09$163.04 -31%

We started the process of determining a valid price forecast for Becton Dickinson & Co with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Becton Dickinson & Co ranked in the 37th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Becton Dickinson & Co, consider:

  • As a business, BDX is generating more cash flow than 87.45% of positive cash flow stocks in the Healthcare.
  • Becton Dickinson & Co's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 22.65% of tickers in our DCF set.
  • Becton Dickinson & Co's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-32%
1%-32%
2%-31%
3%-30%
4%-30%
5%-29%

Want more companies with a valuation profile/forecast similar to that of Becton Dickinson & Co? See DGX, EBS, ICLR, RSCF, and STE.


BDX Latest News Stream


Event/Time News Detail
Loading, please wait...

BDX Latest Social Stream


Loading social stream, please wait...

View Full BDX Social Stream

Latest BDX News From Around the Web

Below are the latest news stories about Becton Dickinson & Co that investors may wish to consider to help them evaluate BDX as an investment opportunity.

Becton, Dickinson's SARS-CoV-2 antigen test OK'd in Europe

Becton, Dickinson & Company (BDX) announces its rapid, point-of-care, SARS-CoV-2 antigen test for use on the BD Veritor Plus System has been CE marked to the IVD Directive (98/79/EC). The new test delivers results in 15 minutes on an easy-to-use, portable instrument. This new assay is expected to be commercial...

Seeking Alpha | September 30, 2020

Becton Dickinson’s 15-minute COVID-19 test cleared for use in Europe

A new coronavirus test that delivers results in just 15 minutes will be available in Europe next month, New Jersey-based medical-device maker Becton Dickinson announced Wednesday. The company expects to start selling its rapid COVID-19 test in the European Union countries by the end of October now that it’s met the requirements to launch the…

New York Post | September 30, 2020

A COVID-19 test that gives results in 15 minutes without a lab has been cleared for use in Europe

Summary List Placement A Becton Dickinson lab-free COVID-19 test that returns results in 15 minutes has been cleared for use in Europe. The US medical device maker said on Wednesday that its testing kit for coronavirus, which has been available in the US since July, met the requirements to be sold in Europe. It will be available in countries that recognize the CE mark, which shows that a manufacturer has ensured a product meets European Union safety requirements. Becton Dickinson said it expects its test to be commercially available in European markets by the end of October. It will most likely be used by emergency departments, pediatricians, and general practitioners, it said. The portable BD Veritor Plus System can quickly identify antigens on the surface of the coronavirus without re...

Business Insider | September 30, 2020

Becton Dickinson reaches $60 million settlement over pelvic mesh devices | Business

The Franklin Lakes, New Jersey-based company said the settlement resolved litigation involving the former CR Bard Inc, which it acquired in 2017. In related court papers, New York Attorney General Letitia James said CR Bard misrepresented or failed to disclose risks associated with the devices, including chronic pain, vaginal scarring, vaginal shortening, infection and inflammation.

Devdiscourse | September 24, 2020

Medical firm probes false-positive COVID-19 tests in US nursing homes

Medical-testing firm Becton Dickinson says it’s investigating false-positive coronavirus test results reported at nursing homes around the US. The New Jersey-based company, also known as BD, said a “small number” of nursing homes are reporting multiple false-positive COVID-19 tests from its Veritor Plus machine, which can deliver results in 15 minutes. Roughly a dozen sites…

New York Post | September 15, 2020

Read More 'BDX' Stories Here

BDX Price Returns

1-mo 7.73%
3-mo -11.03%
6-mo -9.50%
1-year -2.92%
3-year 18.73%
5-year 84.55%
YTD -10.47%
2019 22.20%
2018 6.61%
2017 31.24%
2016 9.22%
2015 12.63%

BDX Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full BDX Dividend History

Continue Researching BDX

Here are a few links from around the web to help you further your research on Becton Dickinson & Co's stock as an investment opportunity:

Becton Dickinson & Co (BDX) Stock Price | Nasdaq
Becton Dickinson & Co (BDX) Stock Quote, History and News - Yahoo Finance
Becton Dickinson & Co (BDX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 1.1862 seconds.